BioAge Labs Inc [BIOA] stock is trading at $20.69, up 15.91%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BIOA shares have gain 34.26% over the last week, with a monthly amount glided 62.27%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioAge Labs Inc [NASDAQ: BIOA] stock has seen the most recent analyst activity on December 05, 2025, when Morgan Stanley upgraded its rating to a Equal-Weight but kept the price target unchanged to $12 for it. Previously, Citigroup upgraded its rating to Buy on October 22, 2025, and kept the price target unchanged to $10. On February 28, 2025, William Blair initiated with a Mkt Perform rating. Morgan Stanley downgraded its rating to an Underweight and decreased its price target to $5 on December 10, 2024. Jefferies downgraded its rating to a Hold and reduced its price target to $7 on December 09, 2024. Citigroup downgraded its rating to Neutral for this stock on December 09, 2024, and downed its price target to $7. In a note dated October 21, 2024, Morgan Stanley initiated an Overweight rating and provided a target price of $40 on this stock.
BioAge Labs Inc [BIOA] stock has fluctuated between $2.88 and $17.90 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. BioAge Labs Inc [NASDAQ: BIOA] shares were valued at $20.69 at the most recent close of the market. An investor can expect a potential drop of -42.0% based on the average BIOA price forecast.
Analyzing the BIOA fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -15.16%, Pretax Profit Margin comes in at -12.81%, and Net Profit Margin reading is -12.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.25 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, BioAge Labs Inc’s Current Ratio is 11.87. Also, the Quick Ratio is 11.87, while the Cash Ratio stands at 8.8. Considering the valuation of this stock, the price to sales ratio is 125.31, the price to book ratio is 2.67.
Transactions by insiders
Recent insider trading involved Fortney Kristen, 10% Owner, that happened on Jan 13 ’26 when 0.23 million shares were purchased. Officer, GOLDSTEIN DOV A MD completed a deal on Jan 13 ’26 to buy 27000.0 shares. Meanwhile, Chief Medical Officer RUBIN PAUL D sold 7433.0 shares on Jan 02 ’26.
